PDCD1 and invasive breast carcinoma: We can potentially evaluate adjuvant immunotherapy (e.g., anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy) in a subset of patients at the highest risk of developing invasive breast cancer.